Klein A, Kaufman H, Arie R, Hoogervorst-Spalter H, Semach E, Barkan A, Martfel J, Servadio C
J Natl Cancer Inst. 1980 Nov;65(5):857-61.
A double-blind study was done on the plasma from 59 hospitalized patients to determine whether a diminished lymphocytic cortisol metabolism-enhancing effect among cancer patients could be used to distinguish them from persons with noncancerous diseases. Known concentrations of human lymphocytes from healthy donors were incubated with cortisol in media containing 50% phosphate-buffered saline (PBS) and 50% of one of the following additives: 1) homologous plasma (HP), 2) plasma from the patient being tested, or 3) additional PBS. Plasma in which the metabolism-enhancing effect was less than 70% of that obtained with HP was considered to be that of a cancer patient. Among the 19 patients known to have cancer, there were only two false-negative results, whereas among the 40 patients diagnosed as having noncancerous diseases, there were six false-positive results. Thus the test findings and the pathologic diagnosis were obviously correlated in approximately 90% of the patients.
对59名住院患者的血浆进行了一项双盲研究，以确定癌症患者淋巴细胞对皮质醇代谢增强作用的减弱是否可用于将他们与非癌症疾病患者区分开来。将已知浓度的来自健康供体的人类淋巴细胞与皮质醇在含有50%磷酸盐缓冲盐水（PBS）和以下添加剂之一的50%的培养基中孵育：1）同源血浆（HP），2）受试患者的血浆，或3）额外的PBS。代谢增强作用小于用HP获得的70%的血浆被认为是癌症患者的血浆。在已知患有癌症的19名患者中，只有两个假阴性结果，而在被诊断患有非癌症疾病的40名患者中，有六个假阳性结果。因此，在大约90%的患者中，测试结果与病理诊断明显相关。
